quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·127d
PRRelease
Nuvectis Pharma Inc. logo

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

NVCT· Nuvectis Pharma Inc.
Health Care
Original source

Companies

  • NVCT
    Nuvectis Pharma Inc.
    Health Care

Recent analyst ratings

  • Apr 2UpdateMaxim Group$17.00
  • Mar 17UpdateLaidlaw$19.00
  • Jul 13UpdateLadenburg Thalmann$21.00
  • Mar 2UpdateHC Wainwright & Co.$14.00

Related

  • PR23d
    Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
  • SEC60d
    SEC Form EFFECT filed by Nuvectis Pharma Inc.
  • SEC69d
    SEC Form S-3 filed by Nuvectis Pharma Inc.
  • SEC71d
    Nuvectis Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • SEC71d
    SEC Form 10-K filed by Nuvectis Pharma Inc.
  • PR71d
    Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
  • INSIDER104d
    Chief Dev. & Ops. Officer Shemesh Shay was granted 150,000 shares, increasing direct ownership by 9% to 1,793,068 units (SEC Form 4)
  • INSIDER104d
    Chairman & CEO Bentsur Ron was granted 150,000 shares, increasing direct ownership by 4% to 3,675,924 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022